LNP

Advanced CAR-T and CAR-NK Engineering Solutions for Next-Generation Cell Therapy Research

 

 

Chimeric Antigen Receptor (CAR) technologies are transforming next-generation cell therapy research by enabling immune cells to recognize and eliminate tumor and other disease-associated cells. However, designing and validating CAR constructs can be complex and time-consuming during early research phases.

Through its partnership with ProMab, Tebubio provides access to a comprehensive toolbox for CAR-T and CAR-NK engineering, including ready-to-use cryopreserved CAR-T cells, over 100 off-the-shelf CAR constructs, non-viral mRNA-LNP immune-cell engineering technologies, and custom CAR development services.

CAR-Engineered T-Cells as Adaptive Immune Effectors

Chimeric Antigen Receptor T (CAR-T) cells are genetically engineered T lymphocytes designed to recognize tumor-associated antigens independently of major histocompatibility complex (MHC) presentation. Upon antigen engagement, CAR signaling triggers T-cell activation, cytotoxicity, cytokine secretion, proliferation, and long-term persistence, forming the basis of adaptive immune memory.

CAR-T Product Portfolio

Find the products???

Real-Time Functional Potency Assay for CAR-T Cells Targeting Solid and Hematological Cancers

Fig. 1: Functional cytotoxicity assay used in ProMab CAR-T development 

CAR-Engineered NK Cells as Innate Immunity Effectors

Chimeric Antigen Receptor NK (CAR-NK) cells are genetically engineered natural killer cells that combine CAR-mediated antigen specificity with endogenous NK-cell cytotoxic mechanisms in an MHC-independent manner. Upon target recognition, CAR-NK cells rapidly induce cytotoxic effector functions while retaining innate immune signaling pathways and a reduced propensity for long-term persistence.

CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo

Virus-Free, without Integration or Electroporation

 

Fig. 2 A-B: 78–95% CAR expression was achieved 16 hours post-transfection in CD19 and BCMA CAR-NK cell.
Fig. 2 C: Preserved NK phenotype: CD56⁺, CD16⁺, CD337⁺, CD3⁻

 

Fig 3: Efficient Target Cell Killing: Real-time cytotoxicity assays demonstrate that CAR-NK cells efficiently eliminate multiple myeloma cells (RPMI-8226 and MM1S) compared to unmodified NK cells.
Dose-Dependent Activity: Increasing CAR-NK effector-to-target ratios significantly enhance tumor cell killing.

Fig. 4: In Vivo Tumor Suppression: In a xenograft mouse model, CD19 CAR-NK cells significantly reduce tumor burden compared with PBS and NK cell controls.

mRNA Tools for Next-Gen Immunotherapy, Gene Editing & Cell Engineering

mRNA Category Application Key Examples
CAR mRNAs Engineering CAR-T/NK cells CD19, BCMA, HER2 – virus-free CAR constructs via mRNA-LNP
Bispecific Ab mRNAs Redirecting T cells to tumors EpCAM–CD3, HER2–CD3 – mRNA-encoded T cell engagers
Checkpoint scFv-Fc / mAbs Blocking immune inhibition PD-1 scFv-Fc, PD-L1 scFv-Fc; full IgGs like Nivolumab (anti-PD-1), Atezolizumab (anti-PD-L1)
Gene Editing / Antigen delivery CRISPR or vaccine studies Cas9-HA, COVID-19 Spike
Immune Modulators Activating or suppressing immune responses IL-4, IL-21, GM-CSF, PD-1, PD-L1 – natural regulators
Stem Cell Factors Reprogramming or iPSC induction Oct-4, SOX2 – pluripotency & lineage conversion
Fluorescent Reporters & mCherry mRNA-LNP Tracking expression visually eGFP, mCherry, Luciferase – for monitoring transfection
Empty LNPs Negative control LNPs without mRNA – for background signal validation

mRNA-LNP Applications Across Immune Cell Types

Infographic of lipid nanoparticle LNP applications for T-cells NK cells macrophages

Application of mRNA-LNP reagents across lymphoid, myeloid, and stem-cell–derived immune systems:

  • Primary T cells
  • NK cells
  • Macrophages
  • Dendritic cells
  • iPSCs and stem-cell–derived immune cells

What Sets ProMab’s CAR Engineering Tools Apart

  • Ready-to-use cryopreserved CAR-T cells for rapid functional studies
  • 100+ CAR constructs available (DNA, mRNA, LNP, or engineered cells)

mRNA-LNP delivery :

  • No cloning. No viral packaging. Fast, streamlined workflows
  • 78–99% transfection efficiency in primary T, NK, iPSC, and dendritic cells
  • Integrated functional assays, including real-time killing, binding, and cytokine analysis
  • Clinically validated technology, supported by 20+ patents and 4 clinical-stage programs (up to Phase II)

Custom Project? Let’s Talk.

Tebubio is the exclusive European scientific interface of ProMab, providing direct access to expertise and tailored CRO support.

  • References


    Article content created by Tebubio using courtesy materials provided by ProMab.